Platelet‐rich plasma for male genital lichen sclerosus resistant to conventional therapy: First prospective study
| Autor: | Alexandra Sujanov, Astrid Guillones, Magdalena Vola, Caroline Agorio, Christopher B Bunker, Cristina Touriño, L. Echarte, Jorge Navarrete |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Male
medicine.medical_specialty Balanitis xerotica obliterans Dermatology Lichen sclerosus Asymptomatic 030207 dermatology & venereal diseases 03 medical and health sciences 0302 clinical medicine Quality of life medicine Humans Sex organ Prospective Studies Prospective cohort study Platelet-Rich Plasma business.industry Balanitis General Medicine Dermatology Life Quality Index medicine.disease Lichen Sclerosus et Atrophicus Circumcision Male 030220 oncology & carcinogenesis Quality of Life medicine.symptom business |
| Zdroj: | Dermatologic Therapy. 33 |
| ISSN: | 1529-8019 1396-0296 |
| DOI: | 10.1111/dth.14032 |
| Popis: | Ultrapotent topical corticosteroids and circumcision are usually effective for male genital lichen sclerosus (MGLSc); however, refractory cases are often referred to our Male Genital Dermatology Unit. Treatment with autologous platelet-rich plasma (TPRP) has recently been advocated as a safe and effective treatment option, but there have been no prospective studies in men to date. The objective of this study is to assess the safety and efficacy of TPRP for MGLSc resistant to conventional therapy. A prospective, open-label, single-arm, therapeutic study was carried out in this study. Inclusion criteria: resistant to conventional therapy for at least 6 months. Procedure: infiltration of 0.1 mL/cm2 PRP every 8 weeks. Monthly data recording: visual appearance with photographs and external scoring by an expert using Investigator's Global Assessment Scale (IGA scale 0-5), symptoms (scale 0-5), quality of life (QoL; Dermatology Life Quality Index [DLQI]), and complications. No. of patients included was n = 5. No. of patients excluded during treatment was n = 1. Mean initial IGA: 3.6. Mean initial DLQI: 6. TPRP n = 34 (range: 2-9; average: 6.8 per patient). Mean IGA at 18 months: 3.25. Mean DLQI at 18 months: 1.25. All patients reported being completely asymptomatic at 10 months. No. of patients with complications is n = 1 (balanitis). TPRP seems to be safe and effective, regarding symptom control and improvement in QoL; however, visual changes were minimal. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|